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ACLACLNOMYCLg A/ETOPOSIDE COMB]gATION THERAPY FOR ADVANCED RE- 
LAPSED ACUTE MYELOID LEUKEMLA " RESULTS OF A PLLOT STUDY Of THE 
ARBEiTSGEMEiNSCHAFT LNTERRLSTLSCNE ONKOLOGLE 
U. Hiddemann, K. Becket', A. Grote-Metke,  R. Kuse, A. Bar tho io -  
mitus, A. ge ichte ,  ] .  Meuthen, D.K. Hossfe id ,  M. Fuchs and Th. 
gOchner 
In a c l in i ca l  phase I I  s tudy actac inomyc in  A (AcLa) and etopos ide  
(VP-16) were g iven in  combinat ion  to 20 pat ients  w i th  acute 
myeto id  Leukemia (AML) at advanced re lapse .  ALL pat ients  had re- 
ce ived a s tandard ized  f i r s t  l i ne  and second Line t reatment  and 
were at re f rac tory  f i r s t  re lapse (n=4) ,  second, th i rd ,  or four th  
re lapse  (n=15) or at relapse af te r  bone marrow t ransp lantat ion  
(n=l ) .  Therapy cons is ted  in AcLa 60 mg/mZ/d and VP-16 100 mg/mZ/d 
both g iven  f rom days 1 to 5. Complete remiss ion  (DR) was achieved 
in 7 pat ients  (35~),  2 cases obta ined a par t ia l  remiss ion  (PR) 
(10%). Five pat ients  d id  not respond (25~) and 6 pat ients  d ied  
w i th in  6 weeks a f te r  the onset of t reatment  (30~) and sere con- 
sidered as ear ly  death.  Tox ic i ty  cons i s ted  main ly  in nausea and 
vomi t ing ,  mucos i t i s ,  severe in fec t ions  and l i ver  enzyme e leva-  
t ions .  Recovery of b lood counts occurred at a median of 25 days, 
the  median t ime to DR or PR was 30 days. 
These data ~ndicate a s ign i f i cant  ant i teukemic  ac t iv i ty  of 
ACia/VP-16 in  heav i ly  p re t reated  pat ients  w i th  advanced re lapsed 
ANL and encourage the cont inu ing  app l i ca t ion  of the two drug com- 
b inat ion  to substant ia te  these f ind ings .  
Department of In te rna l  Medic ine,  Un ivers i ty  of MOnster, ALber t -  
gchwe i tzer -S t r .  33, D-4&OO MOnster, FRG 
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CYTOTOXIC LYMPHOCYTES IN PATIENTS WITH ACUTE MYELOID 
LEUKEMIA BEFORE AND AFTER CHEMOTHERAPY 
E. Kaufhold, H. Garritsen, B. WOrmann, Th. BOchner and W. Hiddemann. 
Cytotoxic activity against allogeneic and autologous leukemic blasts has 
been found in the peripheral blood of patients with acute myeloid leukemia 
(AML) in remission. The effector cells have not been characterized. We have 
examined the absolute and relative numbers of lymphocyte subpopulations 
in 25 patients with newly diagnosed AML. All patients were treated 
according to the protocol of the German Multlcenter Study. Bone marrow 
aspirates and peripheral blood samples were analyzed prior to therapy, in 
aplasia, in complete remission, b~ore consolidation therapy and prior to the 
first maintenance therapy. The samples were prepared by the whole blood 
lysis method. Cells were stained with combinations of monoclonal 
antibodies against CD3, 4, 8, 16, 19, 56, 57 and the gamma/delta T cell 
receptor complex, and were analyzed on a laser - equipped flow cytometer. 
The relative numbers of lymphocytes in the different subpopulations 
correlated closely in simultaneously taken bone marrow aspirates and 
peripheral blood samples. The highest variability in absolute and relative 
numbers was found prior to therapy. The absolute cell numbers in different 
lymphocyte subsets were 40 % (CD8) to 80 % (CD16) lower than those of a 
normal control group. The cell numbers increased slowly. Even before 
maintenance therapy normal values were not reached, whereas the relative 
percentages normalized already during aplasia. The CD57 positive cells 
rose higher after therapy than other cytotoxic lymphocytes. CD19 positive 
cells (B cells) stayed at low levels during the whole obsen/ation period. T 
cells expressing the gamma/delta receptor complex were low prior to 
therapy, but increased in 7 of 10 patients in complete remission with 
pementages of up to 71%. 
The data indicate substantial changes of cytotoxic lymphocytes during the 
clinical course in patients with AML and large interpatient variation. Further 
follow - up will allow correlation of these findings with response and 
remission duration. 
Dept. of Internal Medicine A, Albert-Schweitzer-Str. 33, 4400 MOnster, FRG; 
Department of Applied Physics, University Twente, Enschede, NL. 
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IMMUNO ELECTRON MICROSCOPICAL  ANALYS IS  OF CD34~-  
NAL IZAT ION OF NORMAL MONONUCLEAR BONE MARROWCELLS  
AND LEUKEMIC  BLAST CELLS. 
M. Hartl, G. Hell, E. Beyer - Johannb6ke,  Ch. Sch6pf l in,  
M. Hummel  and E. Kurr le 
The CD34 ant igen (HPCA-I) is supposed to be a regu- 
latory receptor  molecule ,  a l though its st ructure does 
not resemble  any known receptor  system. The aim of 
our ultrastructural studies was to invest igate whether  
the CD34 surface ant igen is modu la ted  via receptor  
med ia ted  endocytos is  as an indirect  ev idence for a 
receptor  funct ion.  Mononuc lear  bone marrow cel ls  
(BMNC), b lasts  of the leukemic cel l  l ine KG- Ia  and 
of four acute leukemias were studied. Immunolabel l ing 
was per fo rmed by an immunegold  technique us ing a two 
step labe l l ing  with the ant i -HPCA- i  MoAb and a GAM- 
gold (30nm) secondary ant ibody. To analyse receptor  
med ia ted  endocytos is  cel ls  were incubated in RPMI 
for var ious  t ime intervals  at 37Oc and 5% CO 2 . To 
eva luate  the surface ant igen express ion  cel ls were 
pre f ixed with g lu tara ldehyde and label led at room 
temperature  in the presence of sod ium azide. BMNC 
were found to have a low ant igen densi ty  combined 
wi th  a h igh rate of internal izat ion.  Immune go ld  
complexes  were loca l i zed in the character i s t i c  struc- 
tures re lated to receptor  med ia ted  endocytos is .  Cel ls  
of the KG-Ia cel l  l ine showed a much h igher  surface 
ant igen density,  but an extremly  low rate of interna- 
l izat ion. The four leukemias studied d isp layed diffe- 
rent surface ant igen dens i t ies  and rates of internal i -  
zation. In all cases h igh ant igen dens i ty  was re lated 
to a low rate of endocytes is  and vice versa. Taken 
together,  ev idence was found that the CD34 surface 
ant igen is a receptor  molecule .  It remains open,  
whether  the impai red in terna l i zat ion  by Some leukemic 
blasts,  espec ia l ly  those of the KG- Ia cel l  l ine, is 
due to an a l tered receptor  funct ion.  
Present adress: Dep. of Internal  Medic ine III, Univer-  
sity C l in ics  Ulm, Robert -Koch-St r .8 ,  7900 Ulm, FRG 
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COLD AGGLUTININ AUTOIMMUNE HAEMOLYTIC ANAEMIA AS SEVERE 
COMPLICATION IN B-CELL ACUTE LYMPHOCYTIC LEUKAEMIA (B-ALL) 
D. S0hngen 1 , G. Meckenstock I , A. Heyll 1 , V. Runde 1 , U. Stoffels 1 , 
W. Schneider 1, H.T. Br0ster 2 and P. Wernet 2 
Autoimmune haemolytic anaemia (AIHA) is a well known complication in 
patients suffering from malignancies. Up to now we have treated 5 patients 
with acute lymphocytic laukaamia - FAB-subtype L3 (B-ALL) with very 
poor clinical outcome. In no case AIHA was found. So we present a case report 
of a 27 y. old patient, whose B-ALL was not only complicated by leukaemic 
menigitis, acute anuric renal failure according to tumour lysis syndrome, 
but also severe cold agglutinin AIHA and without response after allogenic bone 
marrow transplantation (aBMT). Acute intravascular haemolysis occured 
three days after transfusion of 2 red blood cell concentrates (RBC) with 
subsequent fall of hemoglobin from 101 to 61 g/I (max. serum bilirubin 
54.7 p.mol/I, ind. bilirubin 18.8 p.mol/I). Direct antiglobulintest (DAT) 
became positive (max. titer 1:8, using polyspecific antiglobulin serum) and 
coating of red blood cells with C3d could have been detected (max. titer 1:8, 
using monoclonal antibodies). The ether eluate was negative in antibody (AB) 
screening test. AB-differentiation in patients serum revealed cold agglutinin 
auto anti-I AB (IgM, max. titer 1:2000) without in vitro haemolytic 
activity. Other reasons for haemolysis (e.g. anti-Jka/-Jk b or Donath 
Landsteiner's bithermal AB, bacterial, fungal and viral infections, second 
neoplasia, paroxysmal nocturnal haemoglobinuria, rheumatism) could have 
been excluded. Laboratory testing for compatibility of RBC was difficult for 
high-titer auto anti-I AB; blood products (including bone marrow) had to be 
transfused warm (37oc), preventing further severe haemolysis. 
Interestingly bone marrow immunophenotyping revealed a significant 
monoclonal anti-lgM AB-coating (in all probability identical to auto anti-I 
AB) of blasl cells (43% before and 50% day +61after aBMT), but only 6% 
of peripheral blast cells. Up to day +30 after aBMT no blast cells could be 
detected morpholocically, although DAT was continued to be positive.In 
conclusion, B-ALL may be complicated by severe cold agglutinin AIHA and a 
persisting positive DAT. This may be an early sign of nonresponders after 
BMT, even before morpholocieally blast cells are detectable in bone marrow 
aspirates. Blood products have to be transfused warm (37oc). 
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